Randomised, open-label, multicentre trial comparing haemodialysis plus haemoperfusion versus haemodialysis alone in adult patients with end-stage renal disease (HD/HP vs HD): study protocol

Wei Lu, Geng-Ru Jiang, HD/HP versus HD trial Group, Geng-Ru Jiang, Xiao-Qiang Ding, Zhao-Hui Ni, Xiao-Nong Chen, Wei-Jie Yuan, Nian-Song Wang, Zhi-Yong Guo, Feng Ding, Yue-Yi Deng, Chen Yu, Rong Zhou, Wei Lu, Geng-Ru Jiang, HD/HP versus HD trial Group, Geng-Ru Jiang, Xiao-Qiang Ding, Zhao-Hui Ni, Xiao-Nong Chen, Wei-Jie Yuan, Nian-Song Wang, Zhi-Yong Guo, Feng Ding, Yue-Yi Deng, Chen Yu, Rong Zhou

Abstract

Introduction: Haemodialysis (HD) is the cornerstone treatment for patients with end-stage renal disease (ESRD). However, highly protein bound or large molecular weight uremic toxins such as phenolic and indolic compounds and homocysteine, which are associated with adverse outcomes such as cardiovascular disease of patients with ESRD, are difficult to remove via HD but can be effectively eliminates by haemoperfusion (HP). The proposed trial (referred to as HD/HP vs HD below) is a randomised, open-label, multicentre trial comparing HD plus HP versus HD alone in adult patients with ESRD. The primary endpoint measure is all-cause mortality.

Methods and analysis: We plan to enrol 1364 maintenance HD patients from 11 medical centres in Shanghai. Participants will be randomised to receive HD plus HP or HD alone at a 1:1 ratio after 1-month run-in period. In both arms, patients will receive low-flux HD at a frequency of two times a week and haemodiafiltration at a frequency of once a week. In the intervention group, subjects also received HP once every 2 weeks. Follow-up is scheduled at 3, 6, 12, 18 and 24 months after randomisation, and will consist the following: routine physical examinations, standard lab panels (blood routine, liver/residual kidney functions, tests of the coagulation system, etc), dialysis adequacy (standard Kt/V), chest X-ray, ECG, echocardiography, heart function rating. Adverse events will be assessed according to the international conference on harmonisation guidelines. The primary outcome is 24-month all-cause mortality. Secondary outcomes will include cardiovascular-related mortality, the occurrence of major cardiovascular events and the quality of life.

Ethics and dissemination: The study protocol has been approved by the Ethical Committees of all 11 participating centres. Clinical Research Unit of Xin Hua Hospital will oversee the study. The results will be presented at national and international academic meetings, and submitted to peer-reviewed journals for publications.

Trial registration number: NCT03227770; Pre-results.

Keywords: hemodialysis; hemoperfusion; mortality.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flow diagram of the HD/HP versus HD trial. HD, haemodialysis; HP, haemoperfusion; MHD, maintenance haemodialysis.
Figure 2
Figure 2
A schematic diagram of haemodialysis (HD) plus haemoperfusion (HP) treatment.

References

    1. Matsushita K, van der Velde M, Astor BC, et al. . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–81. 10.1016/S0140-6736(10)60674-5
    1. U.S. Renal Data System. USRDS 2017 Annual Data Report.
    1. Hanafusa N, Nakai S, Iseki K, et al. . Japanese society for dialysis therapy renal data registry-a window through which we can view the details of Japanese dialysis population. Kidney Int Suppl 2015;5:15–22. 10.1038/kisup.2015.5
    1. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol 2013;38:136–48. 10.1159/000351758
    1. Vanholder R, De Smet R, Glorieux G, et al. . Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934–43. 10.1046/j.1523-1755.2003.00924.x
    1. Vanholder R, Van Laecke S, Glorieux G. What is new in uremic toxicity? Pediatr Nephrol 2008;23:1211–21. 10.1007/s00467-008-0762-9
    1. Lesaffer G, De Smet R, Lameire N, et al. . Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50–7. 10.1093/ndt/15.1.50
    1. London GM, Marty C, Marchais SJ, et al. . Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943–51. 10.1097/01.ASN.0000129337.50739.48
    1. Furuya R, Kumagai H, Miyata T, et al. . High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin Exp Nephrol 2012;16:421–6. 10.1007/s10157-011-0573-3
    1. Vanholder R, Schepers E, Pletinck A, et al. . An update on protein-bound uremic retention solutes. J Ren Nutr 2012;22:90–4. 10.1053/j.jrn.2011.10.026
    1. Bammens B, Evenepoel P, Verbeke K, et al. . Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004;44:278–85. 10.1053/j.ajkd.2004.04.033
    1. Mandolfo S, Borlandelli S, Imbasciati E. Leptin and beta2-microglobulin kinetics with three different dialysis modalities. Int J Artif Organs 2006;29:949–55. 10.1177/039139880602901005
    1. Chen SJ, Jiang GR, Shan JP, et al. . Combination of maintenance hemodialysis with hemoperfusion: a safe and effective model of artificial kidney. Int J Artif Organs 2011;34:339–47. 10.5301/IJAO.2011.7748
    1. Li WH, Yin YM, Chen H, et al. . Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine 2017;96:e6160 10.1097/MD.0000000000006160
    1. Raine A, Cordonnier D, Ritz E. Effect of hematodialysis plus hemoperfusion on insulin resistance and nutritional status of patients with end-stage diabetic nephropathy. J Int Transl Med 2015;51:180–4.
    1. Zhang J, Yuan Y, An X, et al. . Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus. Int J Clin Exp Med 2016;9:8563–8.
    1. Zhang Y, Mei CL, Rong S, et al. . Effect of the combination of hemodialysis and hemoperfusion on clearing advanced glycation end products: a prospective, randomized, two-stage crossover trial in patients under maintenance hemodialysis. Blood Purif 2015;40:127–32. 10.1159/000376604
    1. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and blood vessels. Boston: Little Brown, 1964.
    1. Hays RD, Kallich JD, Mapes DL, et al. . Kidney Disease Quality of Life Short Form (KDQOL-SF), Version 1.3: a manual for use and scoring. Santa Monica, CA: RAND, 1997.
    1. Obi Y, Rhee CM, Mathew AT, et al. . Residual kidney function decline and mortality in incident hemodialysis patients. J Am Soc Nephrol 2016;27:3758–68. 10.1681/ASN.2015101142
    1. International Conference on Harmonisation. Clinical safety data management: definitions and standards for expedited reporting E2A: International Conference on Harmonisation, 1994.
    1. International Conference on Harmonisation. Post-approval safety data management: definitions and standards for expedited reporting E2D: International Conference on Harmonisation, 2003.
    1. Ghannoum M, Bouchard J, Nolin TD, et al. . Hemoperfusion for the treatment of poisoning: technology, determinants of poison clearance, and application in clinical practice. Semin Dial 2014;27:350–61. 10.1111/sdi.12246

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi